QT interval prolongation and cardiac risk assessment for novel drugs
QT interval prolongation and cardiac risk assessment for novel drugs
- Post published:October 22, 2003
- Post category:Cardiovascular system / Publications
You Might Also Like

The usefulness of non-human primates in central nervous system safety pharmacology

Anxiolytic-like effects of the prototypical meta botropic glutamate receptor 5 antagonist 2-methyl-6-( phenylethynyl) pyridine in rodents.
